arrow_backToday
Archive
1689 items, newest first. Nothing is deleted.
Tuesday, 8 September 2026
Interventions to Improve Outpatient Follow-up for Hospitalized Patients With Alcohol Use Disorder : A Systematic Review.
Eight interventions (38%) reported improved linkage to outpatient follow-up. Across RCTs, effect sizes ranged from an 8% absolute decrease to a 30% absolute increase in outpatient follow-up.
Medicine · Annals · 8 Sept
Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex : A Prospective Cohort Study.
All-cause mortality was U-shaped. Compared with the reference group, 10-year SCI was 4.5% versus 12.5% when hemoglobin was more than 2 g/dL below threshold (ARD +8.1 percentage points; 95% CI 6.7 to 9.4; HR 2.87, CI 2.54 to 3.25).
Medicine · Annals · 8 Sept
Tuberculosis.
Prompt diagnosis, isolation, and treatment improve patient outcomes and reduce transmission. Treatment requires multiple antibiotics for 4 to 9 months, guided by drug sensitivity testing.
Medicine · Annals · 8 Sept
Tozorakimab to Prevent COPD Exacerbations.
In former smokers, annualized moderate or severe exacerbations were 1.34 vs 1.90 in OBERON (rate ratio, 0.71; 95% CI, 0.57 to 0.88; P = 0.002) and 1.37 vs 2.07 in TITANIA (rate ratio, 0.66; 95% CI, 0.55 to 0.80; P<0.001). In the overall population, rates were 1.41 vs 2.00 and 1.44 vs 2.03, respectively.
Medicine · NEJM · 8 Sept
Wildfire smoke and health: current evidence, mechanisms, and future challenges.
No primary outcome or effect estimate reported. Authors state key gaps persist: long-term health effects, interactions with pre-existing conditions, and health disparities.
General Medicine · Lancet · 8 Sept
Effectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study.
Adjusted vaccine effectiveness against medically attended outpatient laboratory-confirmed influenza was 73.1% (95% CI 66.3-78.5). Influenza was confirmed in 703 (14%) of 4975 participants.
General Medicine · Lancet regional health. Southeast Asia · 8 Sept
Effect of Delayed Presentation on the Prognosis of Snakebite Victims at a Tertiary Care Hospital: The Golden Hour Matters
Mortality was 75% (3/4) in the 18-24-hour group versus 7.1% (1/14) in the zero-to-six-hour group. Recovery was highest in the zero-to-six-hour group at 71.4%.
General Medicine · Cureus · 8 Sept
Prenatal Use of Sirolimus in Fetal Therapy: Current Evidence, Clinical Applications, and Future Directions
Case reports describe regression of symptomatic cardiac rhabdomyomas and improvement in outflow obstruction, arrhythmia, hydrops, or impending fetal compromise. No controlled data.
Obstetrics & Gynaecology · Cureus · 8 Sept
Monday, 7 September 2026
Perioperative Systemic Analgesia in Patients With Inflammatory Skin Disease: A Matched Cohort Study
30-day opioid use lower in inflammatory cohort: 3.2% vs 7.0% (RD -3.8 percentage points, 95% CI -4.2 to -3.4; RR 0.46, 95% CI 0.42-0.50). Pain similar at 30 days, higher later.
Anaesthesiology · Cureus · 7 Sept
Adverse and Positive Childhood Experiences and Suicidal Ideation in US Children and Adolescents: A Systematic Review and Meta-Analysis
Highest ACE category vs none: pooled relative estimate 7.19 (95% CI 5.66-9.14). Each additional ACE: odds ratio 1.60 (95% CI 1.52-1.69).
Psychiatry · Cureus · 7 Sept
BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
This could accelerate CAR-T development for pediatric brain tumors, a setting where current options are limited and trial access may expand for children with refractory disease.
Medicine · Fierce Biotech · 7 Sept
Deep Learning Algorithms for the Diagnosis and Staging of Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
Pooled sensitivity 95% (95% CI 91.5%-97.1%), specificity 97.4% (95% CI 95.3%-98.6%) for ROP identification; heterogeneity I²=0.75.
Medicine · Cureus · 7 Sept
Yield and Predictors of Histologically Confirmed Colorectal Polyps in Adults Younger Than 45 Years Undergoing Non-screening Colonoscopy: A Retrospective Cohort Study
Polyps in 217/727 (29.8%; 95% CI, 26.6%-33.3%); neoplastic lesions in 139/727 (19.1%); advanced neoplasia in 33/727 (4.5%), including 4 invasive cancers. Age 40-43 odds ratio 3.84 (95% CI, 2.31-6.38).
Gastroenterology · Cureus · 7 Sept
Deepinder Goyal’s Temple Takes First Step Towards Validating Its Wearable
If validated, this wearable could offer non-invasive brain flow monitoring in clinics, aiding early detection of neurological conditions.
Neurology · Inc42 · 7 Sept
Imaging Pulmonary Embolism in the Era of Subsegmental Clots: What the Internist Needs to Know About Overdiagnosis, Anticoagulation, and Follow-Up
Short-term recurrence rates in SSPE are low and do not differ significantly from proximal PE. No randomized controlled trial data guide anticoagulation; selected low-risk patients may be safely observed.
General Medicine · Cureus · 7 Sept
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
If you manage CKD patients, this anti-inflammatory agent's failure removes a potential option to slow progression; reconsider trial enrollment.
Medicine · Fierce Biotech · 7 Sept
When an Extra X Means Extra Risk: Venous Thromboembolism in Klinefelter Syndrome
Massive bilateral pulmonary embolism with concurrent DVT occurred despite normal hematocrit (48.8% at admission, normal over 13 months), negative thrombophilia panel, implicating KS-intrinsic hypercoagulability.
General Medicine · Cureus · 7 Sept
Acupuncture-Induced Pneumothorax Following Thoracic Acupuncture in a Patient With Ehlers-Danlos Syndrome: A Case Report
Left apical pneumothorax (2.8 cm) developed; aspiration removed 450 mL air, but repeat imaging showed minimal reduction; resolved spontaneously within 24 hours.
General Medicine · Cureus · 7 Sept
Ranolazine in Chronic Stable Angina: A Systematic Review and Meta-Analysis
Exercise duration increased by 33.1 seconds (95% CI 27.3-38.9). MI risk reduced (RR 0.91; 95% CI 0.84-0.98), CABG (RR 0.55; 95% CI 0.35-0.86), any revascularization (RR 0.77; 95% CI 0.64-0.91). Adverse events more frequent (RR 1.45; 95% CI 1.27-1.66).
Cardiology · Cureus · 7 Sept
Global lung cancer screening lessons offer roadmap for India: AIIMS expert
Prioritise high-risk groups and integrate screening with existing systems to make lung cancer detection feasible in India.
Oncology · ETHealthworld · 7 Sept
Real-Time Intelligent Coaching Versus Human Expert Instruction in Surgical Skills Training: A Systematic Review and Meta-Analysis
No significant difference in technical performance (ICEMS and OSATS scores). ICEMS analysis had very high heterogeneity (I²=99%). Coaching reduced overall cognitive load; positive deactivating emotions modestly higher.
General Surgery · Cureus · 7 Sept
Jada System Versus Bakri Balloon for Postpartum Hemorrhage: A Retrospective Cohort Study
No statistically significant differences in blood loss, transfusion, escalation to surgery, or ICU admission between devices.
Obstetrics & Gynaecology · Cureus · 7 Sept
Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah
This lets you identify patients eligible for Etcamah using Guardant’s companion test, so treatment selection can be aligned with the approved biomarker strategy.
Medicine · Fierce Biotech · 7 Sept
IIT Madras patents polymer tech that disintegrates bacteria on surfaces without harming human cells
Offers a non-antibiotic surface coating to curb hospital-acquired infections and superbug spread, potentially reducing reliance on conventional antimicrobials.
General Medicine · ETHealthworld · 7 Sept
PIL challenges Centre’s HPV vaccination drive, seeks Supreme Court intervention over consent, safety and accountability
School-based HPV vaccination may pause; verify consent protocols and legal status before counselling parents or administering doses.
Paediatrics · ETHealthworld · 7 Sept
Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.
No significant difference in time to first wheezing lower respiratory tract illness: 71 (21%) of 342 with OM-85 versus 61 (18%) of 339 with placebo; hazard ratio 1·16 [95% CI 0·82-1·64], p value 0·35.
Medicine · Lancet · 7 Sept
Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody-autoantigen pair in atherosclerosis.
Antibody A6 binds histone H2B with high affinity; vaccination with H2B and adoptive transfer of A6 accelerate atherosclerosis. Anti-H2B titers correlate with aortic calcification in humans.
Medicine · Nature cardiovascular research · 7 Sept
Spatially guided in vivo single-cell functional genomics of postnatal heart.
Identified 21 previously uncharacterized regulators of cardiomyocyte maturation, including genes essential for sarcomere assembly, metabolic reprogramming and electrophysiological transitions.
Medicine · Nature cardiovascular research · 7 Sept
Sunday, 6 September 2026
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
IPO funds will advance siRNA drugs targeting multiple diseases; watch for efficacy data that could expand your therapeutic options.
Medicine · Fierce Biotech · 6 Sept
FSSAI to tighten scrutiny, weighs central ban on non-dairy paneer
A central ban would curb adulterated analogue paneer in your patients' diets, reducing risks from undeclared fats and additives.
General Medicine · ETHealthworld · 6 Sept
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
An inhaled pulmonary hypertension therapy showing phase 2 benefit could offer a more targeted option for patients who struggle with systemic side effects from oral vasodilators.
Medicine · Fierce Biotech · 6 Sept
The changing therapeutic landscape of small-cell lung cancer.
No quantitative results reported; describes emerging targeted therapies including T-cell engagers, antibody-drug conjugates, radioconjugates, and cell therapies showing early promise.
Oncology · Lancet · 6 Sept
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Overall survival hazard ratio 1.04 (95% CI 0.69-1.58; p=0.58). 2-year OS 82% in both groups. Grade 3+ adverse events 12% vs 3%.
Oncology · Lancet · 6 Sept
Saturday, 5 September 2026
Delhi HC backs NMC: Fragmented foreign medical degrees not enough for FMGE eligibility
If you supervise or train FMGE aspirants, this ruling tightens verification—fragmented foreign training won't qualify, affecting recruitment and credential checks.
General Medicine · ETHealthworld · 5 Sept
Liposuction versus conservative therapy for patients with lipoedema in Germany: a multicentre, randomised controlled clinical trial.
68% (190/278) achieved ≥2-point pain reduction with liposuction vs 8% (10/132) with conservative therapy (OR 26.2, 95% CI 13.1-52.5). Serious adverse events: 8% vs 3%.
General Surgery · Lancet · 5 Sept
Pre-exposure prophylaxis as a complementary vaccination strategy to reduce rabies in Kerala, India: a cost-effectiveness modelling study.
Current practice projected 431 rabies deaths (95% PI 353-523) costing US$50.3 million; PrEP added US$10.5-36.5 million and prevented only ten additional deaths; probability of being optimal ≤12%.
General Medicine · Lancet regional health. Southeast Asia · 5 Sept
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Despite lowering Lp(a), this drug did not cut heart attack or stroke risk—so don't start checking Lp(a) routinely yet.
Cardiology · Fierce Biotech · 5 Sept
FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products
Ensures neonatal intensive care units can keep stocking starter PN for premature infants during potential shortages, preventing treatment delays.
Paediatrics · FDA — Press Announcements · 5 Sept
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
For oncologists in India, this approval signals a new option for advanced breast cancer, but check local availability and cost before changing practice.
Oncology · FDA — Press Announcements · 5 Sept